This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
The Australian: Race Oncology Stock Gains On US FDA Milestone
The Australian reports that The US Food and Drug Authority (FDA) has extended Rare Paediatric Disease Designation (RPDD) to Race’s oncology drug RC220 bisantrene for paediatric acute myeloid leukemia (AML). The RPDD in paediatric AML may qualify Race to be eligible for a Priority Review Voucher (PRV).
Race’s Executive Director, Dr Peter Smith, explains in an interview what the RPDD is and why it is a significant step forward for Race’s paediatric AML program.
Watch the interview and read the full report here.